EGFR and non-small cell lung carcinoma: Interestingly, treatment with BIX did not significantly affect EGFR signaling in EGFR-WT NSCLCs, whereas it markedly decreased the EGFR level and inhibited the phosphorylation of the EGFR signaling components AKT and ERK in EGFR-mutant NSCLC cells (Fig. 1e).